Answers are grounded in this paper and cite their sources.
Herein, we produced and characterized cavrotolimod (formerly AST-008), a 20–30 nanometer-diameter immunostimulatory spherical nucleic acid targeting Toll-like receptor 9 (TLR9), for the treatment of solid tumors such as advanced Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (CSCC). Cavrotolimod agonizes TLR9 to produce T-helper 1 (Th1)-type immune responses. We studied cavrotolimod in two mouse models: in an MCC model (using cavrotolimod monotherapy) and in a CSCC model (monotherapy and combination therapy). In the MCC model, a 7.5 mg/kg intratumoral (IT) dose of cavrotolimod elicited tumor growth inhibition (TGI) of up to 68%. In the CSCC model, treatment with 5.0 and 7.5 mg/kg cavrotolimod alone and in combination with an anti-PD-1 antibody produced tumor growth inhibition (TGI = 33–42%). Cavrotolimod was well-tolerated, induced immune cell population changes in the tumors and blood consistent with TGI, and reduced tumor burden in MCC and CSCC mouse models. Cavrotolimod is a promising nanoparticle therapy for these advanced solid tumors.
No takes yet. Share an insight, caveat, or question.
Mix et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: